Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery

This publication has 103 references indexed in Scilit:

• Towards a new tuberculosis drug: pyridomycin – nature's isoniazid
  EMBO Molecular Medicine, 2012
• Structural analysis of inhibition of Mycobacterium tuberculosis methionine aminopeptidase by bengamide derivatives
  European Journal of Medicinal Chemistry, 2012
• Mycobacterium tuberculosisprotein tyrosine phosphatase (PtpA) excludes host vacuolar-H⁺–ATPase to inhibit phagosome acidification
  Proceedings of the National Academy of Sciences, 2011
• New target for inhibition of bacterial RNA polymerase: ‘switch region’
  Current Opinion in Microbiology, 2011
• Inhibition of Mycobacterium tuberculosis Methionine Aminopeptidases by Bengamide Derivatives
  ChemMedChem, 2011
• Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents
  Proceedings of the National Academy of Sciences, 2010
• Slow Onset Inhibition of Bacterial β-Ketoacyl-acyl Carrier Protein Synthases by Thiolactomycin
  Journal of Biological Chemistry, 2010
• Crystal Structures of Mycobacterium tuberculosis KasA Show Mode of Action within Cell Wall Biosynthesis and its Inhibition by Thiolactomycin
  Structure, 2009
• MptpB, a virulence factor from Mycobacterium tuberculosis, exhibits triple-specificity phosphatase activity
  Biochemical Journal, 2007
• Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties
  Proceedings of the National Academy of Sciences, 2007